Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis.
It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs.
Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Sujal Patel |
Contact Details
Address: 2701 Eastlake Avenue East Seattle, Washington 98102 United States | |
| Phone | 206 333 2001 |
| Website | nautilus.bio |
Stock Details
| Ticker Symbol | NAUT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001808805 |
| CUSIP Number | 63909J108 |
| ISIN Number | US63909J1088 |
| Employer ID | 98-1541723 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Sujal M. Patel | Co-Founder, Chief Executive Officer, President, Secretary and Director |
| Dr. Parag Mallick Ph.D. | Co-Founder, Chief Scientist and Director |
| Anna Mowry | Chief Financial Officer and Treasurer |
| Matthew B. Murphy ESQ. | General Counsel |
| Chris Blessington | Vice President of Corporate Marketing and Communications |
| Kentaro Suzuki | Chief Marketing Officer |
| Gwen E. Weld | Chief People Officer |
| Nick A. Nelson | Chief Business Officer and Senior Vice President of Business Development |
| Dr. Subra Sankar Ph.D. | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | 8-K | Current Report |
| Mar 5, 2025 | SCHEDULE 13D/A | Filing |
| Mar 5, 2025 | SCHEDULE 13D/A | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |